<?xml version="1.0" encoding="UTF-8"?>
<record
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd"
    xmlns="http://www.loc.gov/MARC21/slim">

  <leader>05117naa a22005777i 4500</leader>
  <controlfield tag="001">UMUN-OA-20261005-PPE-060</controlfield>
  <controlfield tag="003">local</controlfield>
  <controlfield tag="005">20261005174856.0</controlfield>
  <controlfield tag="006">m     o  d        </controlfield>
  <controlfield tag="007">cr||||||||||||</controlfield>
  <controlfield tag="008">261005s2020    xx      o    u000 0 eng d</controlfield>
  <datafield tag="024" ind1="7" ind2=" ">
    <subfield code="a">10.1186/s12916-020-01753-0</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
    <subfield code="a">(local)OpenAlex:W3094622981</subfield>
  </datafield>
  <datafield tag="040" ind1=" " ind2=" ">
    <subfield code="a">local</subfield>
    <subfield code="b">eng</subfield>
    <subfield code="c">local</subfield>
  </datafield>
  <datafield tag="041" ind1="0" ind2=" ">
    <subfield code="a">eng</subfield>
  </datafield>
  <datafield tag="100" ind1="0" ind2=" ">
    <subfield code="a">Ruth P. Norris</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="245" ind1="1" ind2="0">
    <subfield code="a">Are there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis /</subfield>
    <subfield code="c">Ruth P. Norris; Rosie Dew; Linda Sharp [and others].</subfield>
  </datafield>
  <datafield tag="264" ind1=" " ind2="1">
    <subfield code="a">[Place of publication not identified] :</subfield>
    <subfield code="b">BioMed Central,</subfield>
    <subfield code="c">2020.</subfield>
  </datafield>
  <datafield tag="300" ind1=" " ind2=" ">
    <subfield code="a">1 online resource (1 article).</subfield>
  </datafield>
  <datafield tag="336" ind1=" " ind2=" ">
    <subfield code="a">text</subfield>
    <subfield code="b">txt</subfield>
    <subfield code="2">rdacontent</subfield>
  </datafield>
  <datafield tag="337" ind1=" " ind2=" ">
    <subfield code="a">computer</subfield>
    <subfield code="b">c</subfield>
    <subfield code="2">rdamedia</subfield>
  </datafield>
  <datafield tag="338" ind1=" " ind2=" ">
    <subfield code="a">online resource</subfield>
    <subfield code="b">cr</subfield>
    <subfield code="2">rdacarrier</subfield>
  </datafield>
  <datafield tag="500" ind1=" " ind2=" ">
    <subfield code="a">Publication type: Review article.</subfield>
  </datafield>
  <datafield tag="500" ind1=" " ind2=" ">
    <subfield code="a">Linked open-access copy: published version.</subfield>
  </datafield>
  <datafield tag="506" ind1="0" ind2=" ">
    <subfield code="a">Open access; no subscription required for the linked open-access version.</subfield>
    <subfield code="f">Unrestricted online access</subfield>
    <subfield code="2">star</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
    <subfield code="a">BACKGROUND: Novel biological and precision therapies and their associated predictive biomarker tests offer opportunities for increased tumor response, reduced adverse effects, and improved survival. This systematic review determined if there are socio-economic inequalities in utilization of predictive biomarker tests and/or biological and precision cancer therapies. METHODS: MEDLINE, Embase, Scopus, CINAHL, Web of Science, PubMed, and PsycINFO were searched for peer-reviewed studies, published in English between January 1998 and December 2019. Observational studies reporting utilization data for predictive biomarker tests and/or cancer biological and precision therapies by a measure of socio-economic status (SES) were eligible. Data was extracted from eligible studies. A modified ISPOR checklist for retrospective database studies was used to assess study quality. Meta-analyses were undertaken using a random-effects model, with sub-group analyses by cancer site and drug class. Unadjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed for each study. Pooled utilization ORs for low versus high socio-economic groups were calculated for test and therapy receipt. RESULTS: Among 10,722 citations screened, 62 papers (58 studies; 8 test utilization studies, 37 therapy utilization studies, 3 studies on testing and therapy, 10 studies without denominator populations or which only reported mean socio-economic status) met the inclusion criteria. Studies reported on 7 cancers, 5 predictive biomarkers tests, and 11 biological and precision therapies. Thirty-eight studies (including 1,036,125 patients) were eligible for inclusion in meta-analyses. Low socio-economic status was associated with modestly lower predictive biomarker test utilization (OR 0.86, 95% CI 0.71-1.05; 10 studies) and significantly lower biological and precision therapy utilization (OR 0.83, 95% CI 0.75-0.91; 30 studies). Associations with therapy utilization were stronger in lung cancer (OR 0.71, 95% CI 0.51-1.00; 6 studies), than breast cancer (OR 0.93, 95% CI 0.78-1.10; 8 studies). The mean study quality score was 6.9/10. CONCLUSIONS: These novel results indicate that there are socio-economic inequalities in predictive biomarker tests and biological and precision therapy utilization. This requires further investigation to prevent differences in outcomes due to inequalities in treatment with biological and precision therapies.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="a">Creative Commons Attribution (licence family recorded by the source; version not supplied in metadata).</subfield>
    <subfield code="u">https://openalex.org/W3094622981</subfield>
  </datafield>
  <datafield tag="546" ind1=" " ind2=" ">
    <subfield code="a">In English.</subfield>
  </datafield>
  <datafield tag="588" ind1="0" ind2=" ">
    <subfield code="a">Description generated from OpenAlex bibliographic metadata retrieved on 5 October 2026; full text linked from the source.</subfield>
  </datafield>
  <datafield tag="590" ind1=" " ind2=" ">
    <subfield code="a">Course allocation: B. Sc. Politics, Philosophy and Economics.</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">socioeconomic disparities</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">precision oncology</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">health care utilization</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">health disparities</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">lung cancer</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">breast cancer</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">B. Sc. Politics, Philosophy and Economics</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">UMUN open access collection</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">economic inequality</subfield>
  </datafield>
  <datafield tag="655" ind1=" " ind2="4">
    <subfield code="a">Review articles.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Rosie Dew</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Linda Sharp</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Alastair Greystoke</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Stephen Rice</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Kristina Johnell</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Adam Todd</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
    <subfield code="t">BMC Medicine</subfield>
    <subfield code="g">Vol. 18, no. 1, (2020), pages/article 282</subfield>
    <subfield code="x">1741-7015</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
    <subfield code="u">https://bmcmedicine.biomedcentral.com/track/pdf/10.1186/s12916-020-01753-0</subfield>
    <subfield code="y">Read open-access publication</subfield>
    <subfield code="z">Open access. Access and licence reported by the source; this host could not be independently checked by automation.</subfield>
    <subfield code="7">0</subfield>
  </datafield>
  <datafield tag="884" ind1=" " ind2=" ">
    <subfield code="a">Course selection and automated MARC21 enrichment from OpenAlex metadata.</subfield>
    <subfield code="g">20261005</subfield>
    <subfield code="k">https://openalex.org/W3094622981</subfield>
    <subfield code="q">local</subfield>
  </datafield>
  <datafield tag="942" ind1=" " ind2=" ">
    <subfield code="n">0</subfield>
  </datafield>
  <datafield tag="999" ind1=" " ind2=" ">
    <subfield code="c">1072</subfield>
    <subfield code="d">1072</subfield>
  </datafield>
</record>
